The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - A post-hoc analysis of a Phase 3, single-arm, open-label trial

Atherosclerosis

Volumn 240, Issue 2, 2015, Pages 408-414

  Stefanutti, C ^a   Blom, D J ^b   Averna, M R ^c   Meagher, E A ^d   Theron, H dT ^e   Marais, A D ^b   Hegele, R A ^f   Sirtori, C R ^g   Shah, P K ^h   Gaudet, D ⁱ   Vigna, G B ^j   Sachais, B S ^d   Di Giacomo, S ^a   du Plessis, A M E ^k   Bloedon, L T ^l   Balser, J ^m   Rader, D J ^d   Cuchel, M ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF PALERMO   (Italy)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Netcare   (South Africa)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g OSPEDALE NIGUARDA CA GRANDA   (Italy)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ UNIVERSITÉ DE MONTRÉAL   (Canada)

^j UNIVERSITY OF FERRARA   (Italy)

^k UNIVERSITY OF PRETORIA   (South Africa)

^l Aegerion Pharmaceuticals   (United States)

^m Veristat   (United States)

more..

Author keywords

Homozygous familial hypercholesterolaemia; Lipoprotein apheresis; Lomitapide

Indexed keywords

LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BENZIMIDAZOLE DERIVATIVE; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN A;

ADJUVANT THERAPY; ADULT; APHERESIS; ARTICLE; CANADA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; UNITED STATES; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; HOMOZYGOTE; HYPERLIPOPROTEINEMIA TYPE II; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTICHOLESTEREMIC AGENTS; BENZIMIDAZOLES; BIOMARKERS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEIN(A); MALE; PHENOTYPE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84927729932     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.03.014     Document Type: Article

References (32)

1. Cuchel M., Bruckert E., Ginsberg H.N., Raal F.J., Santos R.D., Hegele R.A., Kuivenhoven J.A., Nordestgaard B.G., Descamps O.S., Steinhagen-Thiessen E., Tybjaerg-Hansen A., Watts G.F., Averna M., Boileau C., Boren J., Catapano A.L., Defesche J.C., Hovingh G.K., Humphries S.E., Kovanen P.T., Masana L., Pajukanta P., Parhofer K.G., Ray K.K., Stalenhoef A.F., Stroes E., Taskinen M.R., Wiegman A., Wiklund C., Chapman M.J. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur. Heart J. 2014, 35:2146-2157. For the European Atherosclerosis Society Consensus Panel on Familial H. 10.1093/eurheartj/ehu274.
2. Goldberg A.C., Hopkins P.N., Toth P.P., Ballantyne C.M., Rader D.J., Robinson J.G., Daniels S.R., Gidding S.S., de Ferranti S.D., Ito M.K., McGowan M.P., Moriarty P.M., Cromwell W.C., Ross J.L., Ziajka P.E. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J.Clin. Lipidol. 2011, 5:133-140. 10.1016/j.jacl.2011.03.001.
3. Harada-Shiba M., Arai H., Oikawa S., Ohta T., Okada T., Okamura T., Nohara A., Bujo H., Yokote K., Wakatsuki A., Ishibashi S., Yamashita S. Guidelines for the management of familial hypercholesterolemia. J.Atheroscler. Thromb. 2012, 19:1043-1060.
4. Jacobson T.A., Ito M.K., Maki K.C., Orringer C.E., Bays H.E., Jones P.H., McKenney J.M., Grundy S.M., Gill E.A., Wild R.A., Wilson D.P., Brown W.V. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J.Clin. Lipidol. 2014, 8:473-488. 10.1016/j.jacl.2014.07.007.
5. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., Wiklund O., Hegele R.A., Raal F.J., Defesche J.C., Wiegman A., Santos R.D., Watts G.F., Parhofer K.G., Hovingh G.K., Kovanen P.T., Boileau C., Averna M., Boren J., Bruckert E., Catapano A.L., Kuivenhoven J.A., Pajukanta P., Ray K., Stalenhoef A.F., Stroes E., Taskinen M.R., Tybjaerg-Hansen A. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus Statement of the European Atherosclerosis Society. Eur. Heart J. 2013, 34:3478a-3490a. For the European Atherosclerosis Society Consensus P. 10.1093/eurheartj/eht273.
6. Watts G.F., Gidding S., Wierzbicki A.S., Toth P.P., Alonso R., Brown W.V., Bruckert E., Defesche J., Lin K.K., Livingston M., Mata P., Parhofer K.G., Raal F.J., Santos R.D., Sijbrands E.J., Simpson W.G., Sullivan D.R., Susekov A.V., Tomlinson B., Wiegman A., Yamashita S., Kastelein J.J. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int. J. Cardiol. 2014, 171:309-325. 10.1016/j.ijcard.2013.11.025.
7. Gagné C., Gaudet D., Bruckert E., Ezetimibe Study G. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002, 105:2469-2475. 10.1161/01.CIR.0000018744.58460.62.
8. Raal F.J., Pilcher G.J., Panz V.R., van Deventer H.E., Brice B.C., Blom D.J., Marais A.D. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011, 124:2202-2207. 10.1161/CIRCULATIONAHA.111.042523.
9. Catapano A.L., Reiner Z., De Backer G., Graham I., Taskinen M.R., Wiklund O., Agewall S., Alegria E., Chapman M., Durrington P., Erdine S., Halcox J., Hobbs R., Kjekshus J., Filardi P.P., Riccardi G., Storey R.F., Wood D., European Society of C and European Atherosclerosis S ESC/EAS Guidelines for the management of dyslipidaemias the task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:3-46. 10.1093/eurheartj/ehr158.
10. Hudgins L.C., Kleinman B., Scheuer A., White S., Gordon B.R. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am. J. Cardiol. 2008, 102:1199-1204. 10.1016/j.amjcard.2008.06.049.
11. Stefanutti C., Vivenzio A., Di Giacomo S., Mazzarella B., Bosco G., Berni A. Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis. Transfusion 2009, 49:1461-1470. 10.1111/j.1537-2995.2009.02135.x.
12. Thompson G.R., Barbir M., Davies D., Dobral P., Gesinde M., Livingston M., Mandry P., Marais A.D., Matthews S., Neuwirth C., Pottle A., le Roux C., Scullard D., Tyler C., Watkins S. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010, 208:317-321. 10.1016/j.atherosclerosis.2009.06.010.
13. Bambauer R., Bambauer C., Lehmann B., Latza R., Schiel R. LDL-apheresis: technical and clinical aspects. Sci. World J. 2012, 2012:314283. 10.1100/2012/314283.
14. Moriarty P.M., Luyendyk J.P., Gibson C.A., Backes J.M. Effect of low-density lipoprotein apheresis on plasma levels of apolipoprotein e4. Am. J. Cardiol. 2010, 105:1585-1587. 10.1016/j.amjcard.2010.01.018.
15. Schwartz J., Winters J.L., Padmanabhan A., Balogun R.A., Delaney M., Linenberger M.L., Szczepiorkowski Z.M., Williams M.E., Wu Y., Shaz B.H. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J.Clin. Apher. 2013, 28:145-284. 10.1002/jca.21276.
16. Stefanutti C., Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler. Suppl. 2013, 14:19-27. 10.1016/j.atherosclerosissup.2012.10.021.
17. Kroon A.A., van't Hof M.A., Demacker P.N., Stalenhoef A.F. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis 2000, 152:519-526. 10.1016/S0021-9150(00)00371-3.
18. Ito M.K., McGowan M.P., Moriarty P.M. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on familial Hypercholesterolemia. J.Clin. Lipidol. 2011, 5:S38-S45. National Lipid Association Expert Panel on Familial H. 10.1016/j.jacl.2011.04.001.
19. Thompson G.R. Recommendations for the use of LDL apheresis. Atherosclerosis 2008, 198:247-255. Heart-UK LDL Apheresis Working Group. 10.1016/j.atherosclerosis.2008.02.009.
20. Aegerion Pharmaceuticals Inc Juxtapid Prescribing Information 2013.
21. Cuchel M., Meagher E.A., du Toit Theron H., Blom D.J., Marais A.D., Hegele R.A., Averna M.R., Sirtori C.R., Shah P.K., Gaudet D., Stefanutti C., Vigna G.B., Du Plessis A.M., Propert K.J., Sasiela W.J., Bloedon L.T., Rader D.J., Phase 3 Ho FHLSi Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013, 381:40-46. 10.1016/S0140-6736(12)61731-0.
22. Raal F.J., Santos R.D., Blom D.J., Marais A.D., Charng M.J., Cromwell W.C., Lachmann R.H., Gaudet D., Tan J.L., Chasan-Taber S., Tribble D.L., Flaim J.D., Crooke S.T. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:998-1006. 10.1016/S0140-6736(10)60284-X.
23. Genzyme Corporation Kynamro Prescribing Information 2013.
24. Raal F.J., Honarpour N., Blom D.J., Hovingh G.K., Xu F., Scott R., Wasserman S.M., Stein E.A. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2014, 384. ePub ahead of print. 10.1016/S0140-6736(14)61374-X.
25. Tavori H., Giunzioni I., Linton M.F., Fazio S. Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis. Circ. Res. 2013, 113:1290-1295. 10.1161/CIRCRESAHA.113.302655.
26. Harada-Shiba M., Kishimoto I., Makino H., Ogura M., Kurtz C., Honapur N., Xu F., Wasserman S.M., Watts G.F. Efficacy of evolocumab in patients with PCSK9 gain of function mutations. Atherosclerosis 2014, 235:e11.
27. Cuchel M., Bloedon L.T., Szapary P.O., Kolansky D.M., Wolfe M.L., Sarkis A., Millar J.S., Ikewaki K., Siegelman E.S., Gregg R.E., Rader D.J. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N.Engl. J. Med. 2007, 356:148-156. 10.1056/NEJMoa061189.
28. Stefanutti C., Thompson G.R. Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. Curr. Atheroscler. Rep. 2015, 17:465. 10.1007/s11883-014-0465-6.
29. Aegerion Pharmaceuticals Inc Lojuxta Summary of Product Characteristics 2013.
30. Santos R.D., Duell P.B., East C., Guyton J.R., Moriarty P.M., Chin W., Mittleman R.S. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur. Heart J. 2013, 10.1093/eurheartj/eht549.
31. Thompson G.R. LDL apheresis. Atherosclerosis 2003, 167:1-13.
32. Bos S., Yayha R., van Lennep J.E. Latest developments in the treatment of lipoprotein (a). Curr. Opin. Lipidol. 2014, 25:452-460. 10.1097/MOL.0000000000000126.